Sofia Waissbluth1, Angela Chuang2, Álvaro Del Valle2, Marcela Cordova3. 1. Department of Otolaryngology, Complejo Asistencial Dr. Sotero Del Rio, Santiago, Chile. Electronic address: sofia.waissbluth@mail.mcgill.ca. 2. Department of Otolaryngology, Complejo Asistencial Dr. Sotero Del Rio, Santiago, Chile. 3. Department of Pediatric Hematology-Oncology, Complejo Asistencial Dr. Sotero Del Rio, Santiago, Chile.
Abstract
OBJECTIVES: Platinum-based chemotherapy treatments are effective against a variety of pediatric malignancies. However, its use can lead to permanent hearing loss. The aim of this study was to evaluate the long-term effect of platinum chemotherapy on hearing and evaluate its progression. METHODS: Prospective cohort study. All records of pediatric patients receiving platinum-based chemotherapy between 2001 and 2006 were reviewed. Demographics and audiograms performed before, during, and following chemotherapy were analyzed. An updated audiogram and a video head impulse test were performed. A hearing ability questionnaire was also completed. RESULTS: Thirty-nine patients met the inclusion criteria. Of these, 12 patients were included in the study; 14 were deceased, 8 had incomplete data and 5 were excluded for other reasons. Median age at chemotherapy was 4.3 years (range 10 months-14.2 years). Seven patients had received cisplatin, two received carboplatin and three received both agents. Five had also received cranial irradiation. With a median follow-up time of 11.9 years, 58.3% had developed hearing loss and two patients wore bilateral hearing aids; 67% of the patients with hearing loss had worsening of their hearing in the long-term. All patients referred difficulties in various subscales measured by the questionnaire. Three patients had decreased vestibulo-ocular reflex gains. CONCLUSION: Platinum-induced hearing loss in pediatric patients can be progressive and debilitating. A long term audiometric follow-up of at least 10 years is suggested for these patients.
OBJECTIVES:Platinum-based chemotherapy treatments are effective against a variety of pediatric malignancies. However, its use can lead to permanent hearing loss. The aim of this study was to evaluate the long-term effect of platinum chemotherapy on hearing and evaluate its progression. METHODS: Prospective cohort study. All records of pediatric patients receiving platinum-based chemotherapy between 2001 and 2006 were reviewed. Demographics and audiograms performed before, during, and following chemotherapy were analyzed. An updated audiogram and a video head impulse test were performed. A hearing ability questionnaire was also completed. RESULTS: Thirty-nine patients met the inclusion criteria. Of these, 12 patients were included in the study; 14 were deceased, 8 had incomplete data and 5 were excluded for other reasons. Median age at chemotherapy was 4.3 years (range 10 months-14.2 years). Seven patients had received cisplatin, two received carboplatin and three received both agents. Five had also received cranial irradiation. With a median follow-up time of 11.9 years, 58.3% had developed hearing loss and two patients wore bilateral hearing aids; 67% of the patients with hearing loss had worsening of their hearing in the long-term. All patients referred difficulties in various subscales measured by the questionnaire. Three patients had decreased vestibulo-ocular reflex gains. CONCLUSION:Platinum-induced hearing loss in pediatric patients can be progressive and debilitating. A long term audiometric follow-up of at least 10 years is suggested for these patients.
Authors: Johnnie K Bass; Wei Liu; Pia Banerjee; Tara M Brinkman; Daniel A Mulrooney; Amar Gajjar; Alberto S Pappo; Thomas E Merchant; Gregory T Armstrong; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: JAMA Oncol Date: 2020-09-01 Impact factor: 31.777
Authors: David R Freyer; Penelope R Brock; Kay W Chang; L Lee Dupuis; Sidnei Epelman; Kristin Knight; Denise Mills; Robert Phillips; Emma Potter; Demie Risby; Philippa Simpkin; Michael Sullivan; Sandra Cabral; Paula D Robinson; Lillian Sung Journal: Lancet Child Adolesc Health Date: 2019-12-19
Authors: Pattarawadee Prayuenyong; John A Taylor; Stephanie E Pearson; Rachel Gomez; Poulam M Patel; Deborah A Hall; Anand V Kasbekar; David M Baguley Journal: Front Oncol Date: 2018-09-25 Impact factor: 6.244
Authors: Dorota Hojan-Jezierska; Anna Chomiak; Agata Czopor; Maja Matthews-Kozanecka; Anna Majewska; Marta Urbaniak-Olejnik; Teresa Matthews-Brzozowska Journal: Oncol Lett Date: 2020-03-05 Impact factor: 2.967